| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1195: Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable |
|
Medicine details |
|
| Medicine name | daratumumab (Darzalex®) |
| Formulation | 20 mg/ml concentrate for solution for infusion |
| Reference number | 4354 |
| Indication | in combination with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable |
| Company | Janssen-Cilag Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 03/09/2026 |
| NICE guidance | |